CN1679941A - Compound preparation consisting of taurine and medicines for hepatopathy and production thereof - Google Patents
Compound preparation consisting of taurine and medicines for hepatopathy and production thereof Download PDFInfo
- Publication number
- CN1679941A CN1679941A CN 200510004851 CN200510004851A CN1679941A CN 1679941 A CN1679941 A CN 1679941A CN 200510004851 CN200510004851 CN 200510004851 CN 200510004851 A CN200510004851 A CN 200510004851A CN 1679941 A CN1679941 A CN 1679941A
- Authority
- CN
- China
- Prior art keywords
- parts
- ornithine
- taurine
- aspartic acid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A compound medicine is prepared from taurine, the hepatolism treating medicine chosen from aspartic acid or its salt, ornithin or its salt, aspartic acid-ornithin, arginine or its salt, leusine, isoleusine, valine and oxylysine, and optional pharmacologically acceptable additive.
Description
Technical field:
The present invention relates to field of medicaments; a kind of compound medicinal formulation for the treatment of hepatopathy, hepatic encephalopathy and preparation method thereof is provided; it contains taurine and is selected from: at least a in the salt of the salt of Aspartic Acid or Aspartic Acid, ornithine or ornithine, aspartic acid ornithine, arginine or arginic salt, leucine, isoleucine, valine or the I 677 can add the medicine acceptable auxiliary in case of necessity.
Background technology:
China's Patients with Viral Hepatitis is numerous, and clinical treatment is had any problem, and no effect method can make progress and is liver cirrhosis, hepatocarcinoma, prognosis mala; Liver cirrhosis, the hepatic encephalopathy state of an illness are critical, easily cause death.Amino acid drug is having certain curative effect aspect the treatment hepatopathy, generally can play and improve liver metabolism, especially participate in the detoxification processes of liver to ammonia, participate in ornithine cycle as ornithine, Aspartic Acid, arginine etc., it is better to be used for the treatment of the hepatic encephalopathy effect, it is unbalance that leucine, isoleucine and valine can be corrected in the serum branched-chain amino acid and ArAA, prevents the hepatic encephalopathy that the ArAA excessive concentration causes in the brain.Only limit to treat hepatic encephalopathy but these aminoacid medicines have at present, example hydrochloric acid arginine sheet, and new pharmacological research proof can be used for the treatment of liver dysfunction such as viral hepatitis, chemical liver injury, clinical application range remains to be enlarged; The treatment that is used for liver dysfunction that has, but need just can receive curative effect preferably with the drug combination of other liver function protectings.The invention provides a kind of treatment hepatopathy, hepatic encephalopathy curative effect compound medicine preferably, by taurine and following medicine: at least a composition in Aspartic Acid or its optical isomer or their salt, ornithine or its optical isomer or their salt, aspartic acid ornithine, arginine or its optical isomer or their salt, I 677, leucine, isoleucine or the valine.
Taurine be in-vivo content the abundantest contain the sulfonic group beta-amino acids; has biological action widely: can remove oxygen-derived free radicals, suppress lipid peroxidation, blood fat reducing; can keep Premeabilisation of cells pressure, stabilizing cell membrane, have the hepatic cholagogic effect, CCl
4Due to hepatocyte injury have defencive function, can alleviate the hepatic tissue edema, reduce serum alanine aminotransferase, suppress hepatocellular apoptosis, prevent hepatic fibrosis.
Aspartic Acid participates in the synthetic of intracellular nucleic acid, is beneficial to repair the hepatocyte that is damaged.In addition, because Aspartic Acid to the facilitation of tricarboxylic acid cycle metabolic process in the hepatocyte, has promoted the energy in the hepatocyte to generate, make the hepatocellular every function that is damaged be able to rapid recovery.Can promote the drainage of bile and bile pigments, effects such as jaundice eliminating, minimizing liver fat, increase hepatic glycogen are arranged; Promote the T lymphocyte to grow and be divided into the mature T lymphocyte, antiviral and antineoplastic action are arranged.
Aspartic acid ornithine has the metabolic material of the promotion of increasing hepatocyte, improves hepatocellular various metabolic functions; the protection liver plasma membrane; participate in effects such as hepatocellular reparation; the experimental hepatic injury serum of rat acute Aspartic Acid aminotransferase (AST) value due to the carbon tetrachloride increased tangible reduction effect; and hepatocellular degeneration necrosis also obviously alleviates, and ethionine rising triacylglycerol is had certain reduction effect.
Zoopery proves; arginine causes acute rats'liver damage that positive protective effect is arranged to hepatic ischemia reperfusion and thioacetamide (TAA); can obviously alleviate the liver morphological abnormalities changes; significantly reduce Serum ALT value and blood plasma and hepatic tissue MDA content, improved impaired liver microcirculation and hemorheology situation.
I 677 can improve the reaction rate of liver glutathione S-transferase (GST) and since GST can be directly and the catalysis glutathion combine with the cell toxicant material, prevent the cytolipin peroxidating, so impel CCl
4Metabolite CCl
3 -The free radical inactivation has antagonism CCl
4Due to the effect of hepatic injury.
Leucine, isoleucine or valine are human indispensable amino acid, can promote protein synthesis and reduce the protein decomposition, help hepatocellular regeneration and reparation, and can improve hypoproteinemia.
Compound medicinal formulation of the present invention studies have shown that through pharmacological toxicology experimental hepatic injury is had protective effect, and application safety, no overt toxicity.
Summary of the invention:
The invention provides a kind of compound medicinal formulation for the treatment of hepatopathy, hepatic encephalopathy and preparation method thereof.
Compound medicinal formulation of the present invention is made up of with the amino acid drug with liver function protecting, the effect of treatment hepatic encephalopathy the taurine compounds.Can add the medicine acceptable auxiliary in case of necessity.The amino acid drug of taurine compounds and above-mentioned tool liver function protecting, the effect of treatment hepatic encephalopathy is formed compound medicine, has anti-hepatocyte injury, the synergism of the liver protecting function, treatment hepatic encephalopathy.Compound preparation of the present invention can be to be fit to medicinal any dosage form, as injection, tablet, capsule, drop pill, pellet, granule etc.When making pharmaceutical preparation, the medicine acceptable auxiliary that can add comprises filler, binding agent, disintegrating agent, lubricant and the fluidizer of solid preparation; The cosolvent, pH value regulator and the solvent that comprise injection.
Pharmaceutical preparation of the present invention is characterized in that, contains taurine compounds and at least a amino acid drug with liver function protecting, the effect of treatment hepatic encephalopathy.Described taurine compounds is a taurine, and described amino acid drug is selected from: the salt of the salt of Aspartic Acid or Aspartic Acid, ornithine or ornithine, aspartic acid ornithine, arginine or arginic salt, leucine, isoleucine, valine, I 677.
Described Aspartic Acid is the free acid of Aspartic Acid, and the salt of Aspartic Acid is the potassium salt of Aspartic Acid, magnesium salt, sodium salt or calcium salt; Ornithine is the free alkali of ornithine, and the salt of ornithine is the hydrochlorate of ornithine, sulfate, acetate; Arginine is arginic free alkali, and arginic salt is arginic hydrochlorate, sulfate, acetate.
Pharmaceutical preparation of the present invention, preferably per 1000 dosage units contain 100～400 parts of taurines, 100～400 parts of ornithines, 100～800 parts of Aspartic Acids.Specifically be per 1000 dosage units, contain 200 parts of taurines, 200 parts of ornithines, 200 parts of Aspartic Acids.
Preferably per 1000 dosage units contain 100～400 parts of taurines, 100～800 parts of aspartic acids, 100～800 parts of Magnesium Aminosuccinates.Specifically be per 1000 dosage units, contain 200 parts of taurines, 200 parts of aspartic acids, 200 parts of Magnesium Aminosuccinates.
Preferably per 1000 dosage units contain 100～400 parts of taurines, and arginine hydrochloride 100-400 part is formed.Specifically be per 1000 dosage units, contain 200 parts of taurines, 200 parts of arginine hydrochloride.
Preferably per 1000 dosage units contain 100～400 parts of taurines, aspartic acid ornithine 100-600 part.Specifically be per 1000 dosage units, contain 200 parts of taurines, 300 parts of aspartic acid ornithines.
In more than forming, the amount of medicine is calculated by weight, per 1 part can be 1 gram, it also can be 1 kilogram or 1 ton, if with gram is unit, this prescription is formed the pharmaceutical preparation that can be made into 1000 units, and the pharmaceutical preparation of described 1000 units is meant, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000g, oral liquid 1000ml etc., also can make big packing as granule, as the 100-500 bag, specifically can be 100 bags, 125 bags, 200 bags, 250 bags, 500 bags etc., every bag can be used as taking dose 1 time.
More than form, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 125 bags, take the 1-2 bag at every turn, can take 62.5-125 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Pharmaceutical preparation of the present invention, its preparation method are the galenic pharmacy conventional methods, comprise the taurine compounds, have the amino acid drug and the blended step of medicine acceptable auxiliary of liver function protecting, the effect of treatment hepatic encephalopathy.
Pharmaceutical preparation of the present invention, oral formulations preferably, solid orally ingestible more preferably, as tablet, capsule, granule etc. can add an amount of pharmaceutically useful adjuvant, most preferably injection for tablet, capsule, granule, as liquid drugs injection, powder pin, the adjuvant that can add has filler, pH value regulator and an amount of solvent.
Pharmaceutical preparation of the present invention can oral administration usefulness, and can take 1-4 time every day, each 1-3 dosage unit; Also but parenteral administration uses 1 every day, each 1-2 dosage unit.Described dosage unit is meant every dose, as every of tablet, and capsular every etc.
The present invention preferably fills a prescription to form: the prescription that prescription, taurine and the I 677 that prescription, taurine and the ornithine that prescription, taurine and the arginine hydrochloride that prescription, taurine and the aspartic acid that taurine and aspartic acid ornithine are formed, Magnesium Aminosuccinate are formed formed, Aspartic Acid are formed formed.More than prescription contains the taurine and the amino acid drug with liver function protecting, the effect of treatment hepatic encephalopathy of physiology effective dose, can add an amount of medicine acceptable auxiliary if desired.The adjuvant addition can be added according to galenic pharmacy routine techniques means according to the needs of preparation.
Pharmaceutical preparation of the present invention can be made sustained-release preparation in case of necessity, is beneficial to be convenient to use and best absorption, and sustained-release preparation can prepare according to galenic pharmacy routine techniques means.
Medicine of the present invention has the synergism of anti-hepatocyte injury, liver function protecting and treatment hepatic encephalopathy.
Below experiment, but be not limited only to following experiment, in order to the beneficial effect of compound medicinal formulation of the present invention to be described:
1, the compound lyophilized powder of taurine and aspartic acid ornithine composition is to carbon tetrachloride (CCl
4) due to the protective effect of acute liver damage
(1) animal
Male mice in kunming, body weight 18～20g
(2) be subjected to the reagent thing
The lyophilized injectable powder that taurine of the present invention and aspartic acid ornithine are made (hereinafter to be referred as TOA); Self-control taurine injectable powder (hereinafter to be referred as T); Commercially available aspartate for injection ornithine (hereinafter to be referred as OA) faces with the preceding sodium chloride injection dissolved dilution of using.
(3) method and result
Get Kunming mouse, be divided into normal group, model group, TOA treatment group, T treatment group, OA treatment group at random, 12 every group.TOA treatment group, T treatment group, OA treatment organize respectively that tail vein injection gives relative medicine, one week of administration.Matched group and model group mouse tail vein injection equivalent sodium chloride injection.2h after the last administration except that control group mice, presses 10ml/kg disposable celiac injection 0.1%CCl
4The Oleum Arachidis hypogaeae semen solvent causes the acute liver damage model.The 16h posterior orbit is got blood, and centrifuging and taking serum is measured liver function (ALT, AST), and serum superoxide dismutases (SOD), malonaldehyde (MDA).The results are shown in following table (with x ± s):
| Group | ???ALT ???(U/L) | ????AST ????(U/L) | ???SOD ???(NU/ml) | ???MDA ???(umol/L) |
| Normal group model group TOA treatment group OA treatment group T treatment group | ???50.38±8.21 **???476.82±46.38 ???124.65±31.07 **#Δ??????208.74±38.23 **???224.92±45.51 ** | ????208.74±25.46 **????686.13±72.49 ????306.35±28.87 **#Δ????????383.31±39.27 **????421.54±39.27 ** | ???611.64±62.47 **???272.55±48.61 ???537.64±42.27 **#Δ??????419.94±44.37 **???378.49±48.71 ** | ???6.76±1.38 **???22.17±2.08 ???11.22±2.16 **#Δ??????15.42±2.37 **???15.67±1.85 * |
Annotate: compare with model group,
*P＜0.05,
*P＜0.01;
Compare with OA treatment group,
#P＜0.05;
Compare with T treatment group,
ΔP＜0.05.
Experimental result shows that the TOA compound medicine can obviously reduce Serum ALT, the AST of animal pattern, illustrates that this composition of medicine has the protection hepatocyte, safeguards the effect of liver function; And can obviously improve activity of SOD in serum, and reduce MDA content, illustrate that this compound medicine has lipoid peroxidization resistant, can play the removing oxygen-derived free radicals, the effect of protection liver plasma membrane.The curative effect of this compound medicine is better than using separately OA or T treatment.
(4) acute toxicity testing
Mouse tail vein injection TOA lyophilized injectable powder of the present invention records its median lethal dose(LD 50) (LD
50) be 3.8g/kg, be 34.5 times of the normal using dosage of people.Show TOA lyophilized injectable powder safety non-toxic of the present invention.
2, the compound tablet of taurine, aspartic acid, Magnesium Aminosuccinate composition is to carbon tetrachloride (CCl
4) due to the protective effect of acute liver damage
(1) animal
Male mice in kunming, body weight 18～20g
(2) be subjected to the reagent thing
The compound tablet (hereinafter to be referred as TAT) that taurine of the present invention, aspartic acid, Magnesium Aminosuccinate are formed; Commercially available taurine sheet (hereinafter to be referred as TT); Commercially available aspartic acid magnesium sheet (hereinafter to be referred as AT) faces with preceding and dissolves with carboxymethylcellulose sodium solution, and it is standby to be diluted to desired concn.
(3) method and result
Get Kunming mouse, be divided into normal group, model group, TAT treatment group, TT treatment group, AT treatment group at random, 12 every group.TAT treatment group, TT treatment group, AT treatment group are irritated stomach respectively and are given relative medicine, one week of administration.Matched group and model group mouse stomach give the equivalent carboxymethylcellulose sodium solution.2h after the last administration except that control group mice, presses 10ml/kg disposable celiac injection 0.1%CCl
4The Oleum Arachidis hypogaeae semen solvent causes the acute liver damage model.The 16h posterior orbit is got blood, and centrifuging and taking serum is measured liver function (ALT, AST), and serum superoxide dismutases (SOD), malonaldehyde (MDA).The results are shown in following table (with x ± s):
| Group | ????ALT ????(U/L) | ???AST ???(U/L) | ????SOD ????(NU/ml) | ??MDA ??(umol/L) |
| Normal group model group TAT treatment group AT treatment group group TT treatment group | ????52.72±9.34 **????483.25±43.66 ????136.85±34.29 **#Δ????????215.43±41.37 **????208.27±48.63 ** | ???213.48±23.62 **???692.07±86.38 ???315.27±30.26 **#Δ??????392.46±41.63 **???381.79±43.38 ** | ????606.27±54.63 **????264.42±41.28 ????543.19±38.53 **#Δ????????406.37±40.84 **????426.33±42.34 ** | ???7.19±1.16 *???23.08±2.17 ???10.67±2.26 **#Δ??????16.62±2.34 **???15.29±2.07 |
Annotate: compare with model group,
*P＜0.05,
*P＜0.01;
Compare with AT treatment group,
#P＜0.05;
Compare with TT treatment group,
ΔP＜0.05.
Experimental result shows that the TAT compound medicine can obviously reduce Serum ALT, the AST of animal pattern, illustrates that this composition of medicine has the protection hepatocyte, safeguards the effect of liver function; And can obviously improve activity of SOD in serum, and reduce MDA content, illustrate that this compound medicine has lipoid peroxidization resistant, can play the removing oxygen-derived free radicals, the effect of protection liver plasma membrane.The curative effect of this compound medicine is better than using separately AT or TT treatment.
(4) acute toxicity testing
Mouse stomach gives TAT compound tablet of the present invention, with the dosed administration of 6g/kg, does not have any toxicity, when dosage is increased to 50 times of the normal using dosage of people, does not record the LD of TAT compound tablet yet
50, show
TAT compound tablet safety non-toxic of the present invention.
The specific embodiment:
Further specify the present invention by the following examples.
EXAMPLE l: preparation taurine (150 parts)+Magnesium Aminosuccinate potassium (200 parts) conventional tablet
Prescription: 1000
Taurine 150g
Magnesium Aminosuccinate 100g
Aspartic acid 100g
Microcrystalline Cellulose 42g
Starch 70g
Carboxymethyl starch sodium 15g
5% polyvidone, 75% alcoholic solution 20g
Magnesium stearate 3g
Preparation method: taurine was pulverized 80 mesh sieves; Magnesium Aminosuccinate potassium and adjuvant are crossed 80 mesh sieves respectively; take by weighing recipe quantity taurine, Magnesium Aminosuccinate potassium, microcrystalline Cellulose, starch mix homogeneously; polyvidone 75% alcoholic solution with 5% prepares soft material; cross 20 mesh sieves and granulate, in 50 ℃ of dryings, 18 mesh sieve granulate; add carboxymethyl starch sodium, magnesium stearate mixing, direct compression promptly.
Embodiment 2: preparation taurine (200 parts)+Magnesium Aminosuccinate potassium (500 parts) injection
Prescription: 1000 bottles
Taurine 200g
Magnesium Aminosuccinate 250g
Aspartic acid 250g
Water for injection adds to 10000ml
Preparation method: take by weighing the recipe quantity Magnesium Aminosuccinate, aspartic acid joins in the 8000ml solution; stirring and dissolving stirs the dissolving of adding taurine, measures pH value between 6.5～7.5; add 0.1% needle-use activated carbon and be incubated 30 minutes with 60 ℃; filter while hot and take off charcoal, add water for injection to total amount, with the filter membrane fine straining of 0.22 μ m; quantitatively be sub-packed in the ampoule bottle; theoretical every bottle of 10ml is in 100 ℃ of flowing steam sterilization 30min, promptly.
Embodiment 3: preparation taurine (100 parts)+Aspartic Acid-ornithine (200 parts) capsule
Prescription: 1000
Taurine 100g
Aspartic Acid-ornithine 200g
Microcrystalline Cellulose 50g
Starch 92g
Dextrin 50g
Sodium carboxymethyl cellulose 6g
Magnesium stearate 2g
Capsule shells
Preparation method: taurine was pulverized 80 mesh sieves; Aspartic Acid-ornithine and adjuvant are crossed 80 mesh sieves respectively; take by weighing recipe quantity taurine, Aspartic Acid-ornithine, microcrystalline Cellulose, starch, dextrin mix homogeneously, the sodium carboxymethyl cellulose solution with 2%, system soft material; crossing 16 mesh sieves granulates; 50 ℃ of dryings, 14 mesh sieve granulate add magnesium stearate and mix; load in capsule shells, promptly.
Embodiment 4: preparation taurine (200 parts)+arginine hydrochloride (200 parts) ordinary tablet
Prescription: 1000
Taurine 200.0g
Arginine hydrochloride 200.0g
Microcrystalline Cellulose 73.0g
Lactose 40.0g
Hydroxypropyl cellulose 35.0g
Low-substituted hydroxypropyl cellulose 24.0g
Magnesium stearate 2.5
Micropowder silica gel 5.5g
Preparation method: taurine was pulverized 80 mesh sieves; arginine hydrochloride and adjuvant are crossed 80 mesh sieves respectively; take by weighing recipe quantity taurine, arginine hydrochloride, microcrystalline Cellulose, lactose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, micropowder silica gel mix homogeneously; cross 80 mesh sieves, direct powder compression promptly.
Embodiment 5: preparation taurine (400 parts)+leucine (100 parts)+isoleucine (80 parts)+valine (80 parts) granule
Prescription: 1000 bags
Taurine 400g
Leucine 100g
Isoleucine 80g
Valine 80g
Icing Sugar 4150g
Sodium carboxymethyl cellulose 100g
3% polyvidone aqueous solution is an amount of
Preparation method: taurine was pulverized 100 mesh sieves; leucine, isoleucine, valine are crossed 100 mesh sieves respectively; Icing Sugar, sodium carboxymethyl cellulose are crossed 80 mesh sieves respectively; take by weighing taurine, leucine, isoleucine, valine, Icing Sugar, the sodium carboxymethyl cellulose mix homogeneously of recipe quantity, cross 80 mesh sieves, with 3% polyvidone aqueous solution system soft material, 16 mesh sieve granulate; 50 ℃ of dryings; 14 mesh sieve granulate, pack, every bag of 5g.
Embodiment 6: taurine (300 parts)+I 677 (200 parts) tablet
Prescription: 1000
Taurine 300g
I 677 200g
Microcrystalline Cellulose 55
Carboxymethyl starch sodium 24
5% polyvidone, 50% alcoholic solution 18g
Magnesium stearate 3g
Preparation method: taurine was pulverized 80 mesh sieves; I 677, microcrystalline Cellulose, carboxymethyl starch sodium are crossed 80 mesh sieves respectively; with taurine, I 677, microcrystalline Cellulose mix homogeneously; cross 60 mesh sieves,, cross 20 mesh sieves and granulate with 5% polyvidone, 50% alcoholic solution system soft material; 50 ℃ of dryings; 18 mesh sieve granulate add magnesium stearate, carboxymethyl starch sodium mix homogeneously, and direct compression promptly.
Embodiment 7: preparation taurine (400 parts)+ornithine (100 parts) capsule
Prescription: 1000
400 parts of taurines
100 parts of ornithines
Microcrystalline Cellulose 75g
Sodium carboxymethyl cellulose 25g
Capsule shells
Preparation method: taurine was pulverized 80 mesh sieves; ornithine, microcrystalline Cellulose are crossed 80 mesh sieves respectively; take by weighing taurine, ornithine, the microcrystalline Cellulose mixing of recipe quantity; with 2% aqueous solution of sodium carboxymethyl cellulose, the system soft material is crossed 16 mesh sieves and is granulated; 50 ℃ of dryings; 14 mesh sieve granulate are loaded in capsule shells, promptly.
Embodiment 8: preparation taurine (200 parts)+Aspartic Acid (200 parts)+ornithine (200 parts) tablet
Prescription: 1000
Taurine 200g
Aspartic Acid 200g
Ornithine 200g
Microcrystalline Cellulose 65g
Polyvinylpolypyrrolidone 25g
10% polyvidone aqueous solution is an amount of
Pulvis Talci 7g
Magnesium stearate 3g
Preparation method: taurine was pulverized 80 mesh sieves; Aspartic Acid, ornithine and adjuvant are crossed 80 mesh sieves respectively; take by weighing taurine, Aspartic Acid, ornithine, the microcrystalline Cellulose mixing of recipe quantity; with 10% polyvidone aqueous solution system soft material, cross 18 mesh sieves and granulate 50 ℃ of dryings; 16 mesh sieve granulate; add polyvinylpolypyrrolidone, Pulvis Talci, magnesium stearate, mixing, direct compression are promptly.
Claims (10)
1. a compound medicinal formulation for the treatment of hepatopathy, hepatic encephalopathy is characterized in that, contains taurine compounds and at least a amino acid drug with liver function protecting, the effect of treatment hepatic encephalopathy.
2. the compound medicinal formulation of claim 1; it is characterized in that; described taurine compounds is a taurine, and described amino acid drug is selected from: the salt of the salt of Aspartic Acid or Aspartic Acid, ornithine or ornithine, aspartic acid ornithine, arginine or arginic salt, leucine, isoleucine, valine, I 677.
3. claim 2 compound medicinal formulation is characterized in that, described Aspartic Acid is the free acid of Aspartic Acid, and the salt of Aspartic Acid is the potassium salt of Aspartic Acid, magnesium salt, sodium salt or calcium salt; Ornithine is the free alkali of ornithine, and the salt of ornithine is the hydrochlorate of ornithine, sulfate, acetate; Arginine is arginic free alkali, and arginic salt is arginic hydrochlorate, sulfate, acetate.
4. the compound medicinal formulation of claim 3, per 1000 dosage units contain 100～400 parts of taurines, 100～400 parts of ornithines, 100～800 parts of Aspartic Acids.
5. the compound medicinal formulation of claim 4, per 1000 dosage units contain 200 parts of taurines, 200 parts of ornithines, 200 parts of Aspartic Acids.
6. the compound medicinal formulation of claim 6, per 1000 dosage units contain 100～400 parts of taurines, 100～800 parts of aspartic acids, 100～800 parts of Magnesium Aminosuccinates.
7. the compound medicinal formulation of claim 6, per 1000 dosage units contain 200 parts of taurines, 200 parts of aspartic acids, 200 parts of Magnesium Aminosuccinates.
8. the compound medicinal formulation of claim 6, per 1000 dosage units contain 100～400 parts of taurines, and arginine hydrochloride 100-400 part is formed.
9. the compound medicinal formulation of claim 6, per 1000 dosage units contain 200 parts of taurines, 200 parts of arginine hydrochloride.
10. the compound medicinal formulation of claim 6, per 1000 dosage units contain 100～400 parts of taurines, aspartic acid ornithine 100-600 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510004851 CN1679941A (en) | 2005-02-02 | 2005-02-02 | Compound preparation consisting of taurine and medicines for hepatopathy and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510004851 CN1679941A (en) | 2005-02-02 | 2005-02-02 | Compound preparation consisting of taurine and medicines for hepatopathy and production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679941A true CN1679941A (en) | 2005-10-12 |
Family
ID=35066934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510004851 Pending CN1679941A (en) | 2005-02-02 | 2005-02-02 | Compound preparation consisting of taurine and medicines for hepatopathy and production thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679941A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299676C (en) * | 2005-03-15 | 2007-02-14 | 中国人民解放军第三军医大学 | Anti-anoxia medicinal composition |
| CN100371317C (en) * | 2006-08-07 | 2008-02-27 | 江阴南极星生物制品有限公司 | Method for synthesizing taurine arginine salt |
| CN111295187A (en) * | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
| CN113069527A (en) * | 2021-04-20 | 2021-07-06 | 北京天玺宝科技有限公司 | Composition with functions of dispelling effects of alcohol and protecting liver and preparation method thereof |
| US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
-
2005
- 2005-02-02 CN CN 200510004851 patent/CN1679941A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299676C (en) * | 2005-03-15 | 2007-02-14 | 中国人民解放军第三军医大学 | Anti-anoxia medicinal composition |
| CN100371317C (en) * | 2006-08-07 | 2008-02-27 | 江阴南极星生物制品有限公司 | Method for synthesizing taurine arginine salt |
| US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
| US11602511B2 (en) | 2016-12-19 | 2023-03-14 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
| CN111295187A (en) * | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | Amino acid composition for treating liver diseases |
| US11571404B2 (en) | 2017-08-14 | 2023-02-07 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
| CN113069527A (en) * | 2021-04-20 | 2021-07-06 | 北京天玺宝科技有限公司 | Composition with functions of dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN113069527B (en) * | 2021-04-20 | 2022-03-18 | 北京华睿鼎信科技有限公司 | Composition with functions of dispelling effects of alcohol and protecting liver and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN87105828A (en) | The quick-acting compositionss of sulindac or sodium sulindac and alkali | |
| CN101057862A (en) | Medicinal composition for treating senile osteoarthropathy | |
| CN1679941A (en) | Compound preparation consisting of taurine and medicines for hepatopathy and production thereof | |
| CN1682749A (en) | Flavone composition for sobering and liver protection and its use | |
| CN1679615A (en) | Compound infantile energy mistura soluble vitamin preparation and use thereof | |
| CN1245398C (en) | Extraction technology of baicalein, medicinal composition and preparation technology of medicine | |
| CN1357328A (en) | Medicine preparation and its production process | |
| CN1781485A (en) | Improved entecavir oral disintegrating tablet and its preparing method | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1679609A (en) | Compound energy mistura fat-soluble vitamins adult preparation and use thereof | |
| CN1943594A (en) | Oral disintegrating tablet of lysine calcium mono hydrogen phosphate | |
| CN1827095A (en) | Pharmaceutical composition using pregabalin as active ingredient, its preparation method and use | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN1660105A (en) | Disintegration piece taken through oral cavity containing Gimeracil and Oteracil Potassium with fluorine being added | |
| CN1679608A (en) | Compound preparation of inosine, triphosphoadenosine and vitamin C and use thereof | |
| CN1660140A (en) | Activity combination of marine life and application | |
| CN1579376A (en) | Rhizoma-curcumae-longae element-soft cap sule and its preparation method | |
| CN1679940A (en) | Compound preparation of taurine and medicines for protecting liver and its making method | |
| CN1438225A (en) | Ginger-yellow pigment metal-ion complex, its preparation method and use | |
| CN1640396A (en) | Novel medicinal compositions | |
| CN1290543C (en) | Medicinal health protection product | |
| CN101062040A (en) | Stable type cucurbitacin liquid formula and the agent thereof | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1839829A (en) | Antiviral cold compound formulation containing arbidol and taurine | |
| CN1726916A (en) | Oral disintegration tablet for dropping blood sugar and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |